Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
申请人:Krepski R. Larry
公开号:US20070099901A1
公开(公告)日:2007-05-03
Imidazo-quinoline, -pyridine, and -naphthyridine ring systems substituted at the 1-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.
HYDROXYLAMINE AND OXIME SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES
申请人:3M Innovative Properties Company
公开号:EP1686992A2
公开(公告)日:2006-08-09
US8697873B2
申请人:——
公开号:US8697873B2
公开(公告)日:2014-04-15
US8778963B2
申请人:——
公开号:US8778963B2
公开(公告)日:2014-07-15
[EN] HYDROXYLAMINE AND OXIME SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES<br/>[FR] HYDROXYLAMINE, ET IMIDAZOQUINOLEINES, ET IMIDAZOPYRIDINES ET IMIDAZONAPHTYRIDINE SUBSTITUES D'OXIME
申请人:3M INNOVATIVE PROPERTIES CO
公开号:WO2005051324A2
公开(公告)日:2005-06-09
Imidazo-quinoline, -pyridine, and -naphthyridine ring systems substituted at the 1-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.